<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098407</url>
  </required_header>
  <id_info>
    <org_study_id>PRO16020403</org_study_id>
    <secondary_id>1K23DA038789-01A1</secondary_id>
    <nct_id>NCT03098407</nct_id>
  </id_info>
  <brief_title>Opioid Dependence Treatment Therapies in Pregnancy</brief_title>
  <official_title>A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of opioid dependence in pregnancy increased over the last decade from 1.2 to
      5.8 per 1,000 hospital births per year.1 While methadone is the current, standard treatment
      for opioid dependent (OD) pregnant women, buprenorphine recently emerged as an alternative.
      In a recent clinical trial (MOTHER), buprenorphine was associated with superior neonatal
      outcomes such as shorter duration of treatment for neonatal abstinence syndrome (NAS)
      compared to methadone. However, buprenorphine was also associated with greater study
      discontinuation (33% vs. 18%) and illicit opioid use (33% vs. 23%) compared to methadone.
      Treatment dropout often leads to relapse and resumption of high-risk behaviors, overshadowing
      any short-term improvement in neonatal outcomes. Therefore, The goal of this K23 proposal is
      to conduct a pilot study to establish the feasibility and acceptability of a randomized
      comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally
      licensed methadone programs for the treatment of OD pregnant women.

      A pilot study is critical to develop the outcome measures, assessment tools and participant
      tracking techniques necessary for a future, large-scale comparative effectiveness clinical
      trial. An examination of feasibility and acceptability will also allow use to characterize
      the subpopulations of OD pregnant women willing to participate in treatment randomization,
      identify patient and provider characteristics associated with established treatment
      preferences and inform the development of strategies to improve participation and enhance the
      generalizability of the future large-scale clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      The goal of this proposal is to conduct a pilot study to establish the feasibility and
      acceptability of a randomized comparative effectiveness clinical trial comparing office-based
      buprenorphine vs. federally licensed methadone programs for the treatment of opioid dependent
      pregnant women.

      Specific Aims:

      Aim 1: Evaluate the feasibility of conducting a randomized study comparing office-based
      buprenorphine vs. federally licensed methadone programs for the treatment of OD pregnant
      women. OD pregnant women (n=50) will be randomized (1:1) to office-based buprenorphine vs. a
      federally licensed methadone program. Feasibility will be assessed by measuring the
      proportion of OD pregnant women who are eligible, who enroll, who remain in the study and by
      the ability to monitor treatment program factors (e.g. compliance with treatment
      provider/facility visits, counseling sessions, prenatal care visits, social services
      involvement) and maternal treatment outcomes such as treatment retention, illicit drug use
      and HIV risk behavior.

      Aim 2: Describe the perspectives of OD pregnant women and their providers regarding
      buprenorphine vs. methadone for the treatment of opioid dependence in pregnancy. Study
      acceptability will be assessed by conducting qualitative semi-structured interviews with
      three groups: (1) pilot participants to determine their satisfaction with the assigned
      treatment program and identify mismatches between treatment program services and
      participants' needs; (2) prenatal care and opioid treatment providers to identify ways to
      improve the treatment process in pregnancy and to suggest ideas for care coordination; (3) OD
      pregnant women who are ineligible or who choose not to participate in the pilot trial will
      also be asked to participate in an interview to gain a broader perspective of attitudes and
      perspectives regarding opioid treatment programs in pregnancy.

      Aim 3: Identify barriers and facilitators to treatment retention in the postpartum period and
      identify key functional outcomes relevant to reductions in illicit drug use during pregnancy.
      Illicit drug use relapse is most common in the immediate postpartum period when stresses
      associated with motherhood are the greatest. Therefore, pilot participants will be followed
      at 3, 6, 9 and 12 weeks postpartum to identify barriers and facilitators specific to the
      postpartum period that may impact treatment retention. The relationship between postpartum
      treatment retention and maternal functional outcomes will also be explored (e.g.
      breastfeeding, postpartum depression, motherhood satisfaction, infant custody, employment,
      and criminality).

      Background:

      The incidence of opioid dependence in pregnancy increased over the last decade from 1.2 to
      5.8 per 1,000 hospital births per year. While methadone is the current, standard treatment
      for opioid dependent (OD) pregnant women, buprenorphine recently emerged as an alternative.
      In a recent clinical trial (MOTHER), buprenorphine was associated with superior neonatal
      outcomes such as shorter duration of treatment for neonatal abstinence syndrome (NAS)
      compared to methadone. However, buprenorphine was also associated with greater study
      discontinuation (33% vs. 18%) and illicit opioid use (33% vs. 23%) compared to methadone.
      Treatment dropout often leads to relapse and resumption of high-risk behaviors, overshadowing
      any short-term improvement in neonatal outcomes. Therefore, the next research question that
      emerges is which is the most effective treatment (buprenorphine vs. methadone) for a
      particular patient during pregnancy?

      In clinical settings, differences in maternal characteristics, treatment program structure
      and patient and provider preferences may surpass the impact of pharmacology on maternal
      treatment outcomes (treatment retention, illicit drug use, HIV risk behavior). Buprenorphine
      is dispensed in office-based settings by a variety of providers and with less regulatory
      oversight than methadone. Methadone is dispensed from federally licensed facilities that
      often incorporate counseling and support services into treatment protocols. Successful
      office-based treatment relies on shared power and responsibility, close patient-provider
      relationships and careful attention to psychosocial co-morbidities. Failure to match patient
      problem severity to differences in treatment program structure may contribute to adverse
      maternal outcomes. Therefore, to understand the comparative effectiveness of buprenorphine
      vs. methadone in pregnancy, the impact of patient problem severity and treatment program
      structure on maternal (vs. neonatal) outcomes must be compared.

      Significance:

      Findings from this project will provide the preliminary data to support a comparative
      effectiveness clinical trial designed to compare the impact of office-based buprenorphine vs.
      federally licensed methadone programs on maternal treatment and postpartum functional
      outcomes in OD women. The ultimate goal of this line of research is develop evidence-based
      clinical guidelines to guide provider decision-making regarding the most effective treatment
      (buprenorphine vs. methadone) for a particular patient during pregnancy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who are recruited, enrolled, retained, and who complete the study.</measure>
    <time_frame>12 Months</time_frame>
    <description>evaluate a minimum of 9 OD pregnant women per month for possible participation and enrollment, randomize a minimum of 4 participants per month to office-based buprenorphine (PRC) or methadone treatment facility (NATP) for a total of 50 participants over a 12 month enrollment period, retain ≥ 80% of randomized participants until 12 weeks postpartum, and maintain &lt; 5% of incomplete data.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Buprenorphine Maintenance Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methadone Maintenance Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.</description>
    <arm_group_label>Buprenorphine Maintenance Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.</description>
    <arm_group_label>Methadone Maintenance Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women 18+ years old, with a singleton pregnancy ≤ 28 weeks gestation
             confirmed by ultrasound, who meet Diagnostic and Statistical Manual-IV criteria for
             opioid dependence confirmed by urine drug screen (UDS), who are interested in opioid
             maintenance treatment and plan to receive prenatal care and deliver at Magee Womens
             Hospital (MWH) will be recruited.

        Exclusion Criteria:

          -  (1) active, current dependence on benzodiazepines or alcohol

          -  (2) acute severe psychiatric condition in need of immediate treatment (e.g. suicidal
             ideations)

          -  (3) pending or legal action that could prohibit or interfere with participation (e.g.
             incarceration)

          -  (4) current, established treatment with methadone or buprenorphine. Exclusion criteria
             are based on the Substance Abuse and Mental Health Services Administration (SAMHSA)
             recommendations for office-based buprenorphine use.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth E Krans, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magee-Womens Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hollis Laird, MPH</last_name>
    <phone>412-641-2248</phone>
    <email>lairdh2@mwri.magee.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hollis Laird, MPH</last_name>
      <phone>412-641-2248</phone>
      <email>lairdh2@mwri.magee.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth E Krans, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012 May 9;307(18):1934-40. doi: 10.1001/jama.2012.3951. Epub 2012 Apr 30.</citation>
    <PMID>22546608</PMID>
  </reference>
  <reference>
    <citation>Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015 Mar-Apr;9(2):81-6. doi: 10.1097/ADM.0000000000000092.</citation>
    <PMID>25622120</PMID>
  </reference>
  <reference>
    <citation>Jones HE, Heil SH, Baewert A, Arria AM, Kaltenbach K, Martin PR, Coyle MG, Selby P, Stine SM, Fischer G. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012 Nov;107 Suppl 1:5-27. doi: 10.1111/j.1360-0443.2012.04035.x. Review.</citation>
    <PMID>23106923</PMID>
  </reference>
  <reference>
    <citation>Goodman D. Buprenorphine for the treatment of perinatal opioid dependence: pharmacology and implications for antepartum, intrapartum, and postpartum care. J Midwifery Womens Health. 2011 May-Jun;56(3):240-7. doi: 10.1111/j.1542-2011.2011.00049.x. Review.</citation>
    <PMID>21535372</PMID>
  </reference>
  <reference>
    <citation>Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stühlinger G, Pezawas L, Aschauer HN, Kasper S. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999 Sep;94(9):1337-47.</citation>
    <PMID>10615719</PMID>
  </reference>
  <reference>
    <citation>Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359.</citation>
    <PMID>21142534</PMID>
  </reference>
  <reference>
    <citation>Jones ES, Fiellin DA. Women and opioid dependence treatment: office-based versus opioid treatment program-based care? Subst Abus. 2007 Jun;28(2):3-8. doi: 10.1300/J465v28n02_02.</citation>
    <PMID>19266708</PMID>
  </reference>
  <reference>
    <citation>Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients' Reasons for Choosing Office-based Buprenorphine: Preference for Patient-Centered Care. J Addict Med. 2010 Dec;4(4):204-10. doi: 10.1097/ADM.0b013e3181cc9610.</citation>
    <PMID>21170143</PMID>
  </reference>
  <reference>
    <citation>Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013 Jul;40(3):367-77. doi: 10.1007/s11414-013-9341-3.</citation>
    <PMID>23702611</PMID>
  </reference>
  <reference>
    <citation>Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O'Connor PG, Schottenfeld RS. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007 Apr;22(4):527-30.</citation>
    <PMID>17372805</PMID>
  </reference>
  <reference>
    <citation>Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.</citation>
    <PMID>25330017</PMID>
  </reference>
  <reference>
    <citation>Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009 Jan 1;99(1-3):132-40. doi: 10.1016/j.drugalcdep.2008.07.013. Epub 2008 Sep 19.</citation>
    <PMID>18804923</PMID>
  </reference>
  <reference>
    <citation>Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004 Sep;27(2):153-9. Review.</citation>
    <PMID>15450648</PMID>
  </reference>
  <reference>
    <citation>Stine SM, Heil SH, Kaltenbach K, Martin PR, Coyle MG, Fischer G, Arria AM, Selby P, Jones HE. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. Am J Drug Alcohol Abuse. 2009;35(6):429-33. doi: 10.3109/00952990903374080.</citation>
    <PMID>20014912</PMID>
  </reference>
  <reference>
    <citation>Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol. 2009 Sep;201(3):326.e1-6. doi: 10.1016/j.ajog.2009.05.052. Epub 2009 Jul 24.</citation>
    <PMID>19631928</PMID>
  </reference>
  <reference>
    <citation>Cleary BJ, Donnelly JM, Strawbridge JD, Gallagher PJ, Fahey T, White MJ, Murphy DJ. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol. 2011 Feb;204(2):139.e1-9. doi: 10.1016/j.ajog.2010.10.004. Epub 2010 Dec 8.</citation>
    <PMID>21145035</PMID>
  </reference>
  <reference>
    <citation>Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M, Aschauer H. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006 Feb;101(2):275-81.</citation>
    <PMID>16445556</PMID>
  </reference>
  <reference>
    <citation>Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011 Oct;67(10):1053-9. doi: 10.1007/s00228-011-1049-9. Epub 2011 May 3.</citation>
    <PMID>21538146</PMID>
  </reference>
  <reference>
    <citation>Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207. doi: 10.1002/14651858.CD002207.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;2:CD002207.</citation>
    <PMID>18425880</PMID>
  </reference>
  <reference>
    <citation>Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, Cunningham CO. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010 Jul;39(1):51-7. doi: 10.1016/j.jsat.2010.04.001.</citation>
    <PMID>20682186</PMID>
  </reference>
  <reference>
    <citation>Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs. 2014 Nov-Dec;46(5):412-26. doi: 10.1080/02791072.2014.921743.</citation>
    <PMID>25364994</PMID>
  </reference>
  <reference>
    <citation>Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). J Stud Alcohol Drugs. 2013 Jul;74(4):605-13.</citation>
    <PMID>23739025</PMID>
  </reference>
  <reference>
    <citation>Jones HE, Johnson RE, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, Crocetti M, Dudas R, Harrow C, Huestis MA, Jansson LM, Lantz M, Lester BM, Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005 Jul;79(1):1-10.</citation>
    <PMID>15943939</PMID>
  </reference>
  <reference>
    <citation>Holbrook AM, Jones HE, Heil SH, Martin PR, Stine SM, Fischer G, Coyle MG, Kaltenbach K. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug Alcohol Depend. 2013 Sep 1;132(1-2):329-34. doi: 10.1016/j.drugalcdep.2013.02.031. Epub 2013 Mar 21.</citation>
    <PMID>23523131</PMID>
  </reference>
  <reference>
    <citation>Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007 Jun;1(2):62-7. doi: 10.1097/ADM.0b013e3180473c11.</citation>
    <PMID>21768936</PMID>
  </reference>
  <reference>
    <citation>Barry DT, Irwin KS, Jones ES, Becker WC, Tetrault JM, Sullivan LE, Hansen H, O'Connor PG, Schottenfeld RS, Fiellin DA. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009 Feb;24(2):218-25. doi: 10.1007/s11606-008-0881-9. Epub 2008 Dec 17.</citation>
    <PMID>19089500</PMID>
  </reference>
  <reference>
    <citation>Benoit E, Young R, Magura S, Staines GL. The impact of welfare reform on methadone treatment: policy lessons from service providers in New York city. Subst Use Misuse. 2004;39(13-14):2355-90.</citation>
    <PMID>15603008</PMID>
  </reference>
  <reference>
    <citation>Morgenstern J, Hogue A, Dauber S, Dasaro C, McKay JR. A practical clinical trial of coordinated care management to treat substance use disorders among public assistance beneficiaries. J Consult Clin Psychol. 2009 Apr;77(2):257-69. doi: 10.1037/a0014489.</citation>
    <PMID>19309185</PMID>
  </reference>
  <reference>
    <citation>Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009 Nov 1;105(1-2):83-8. doi: 10.1016/j.drugalcdep.2009.06.015. Epub 2009 Jul 21. Erratum in: Drug Alcohol Depend. 2011 Jan 15;113(2-3):252.</citation>
    <PMID>19625142</PMID>
  </reference>
  <reference>
    <citation>Roman PM, Abraham AJ, Rothrauff TC, Knudsen HK. A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S44-52. doi: 10.1016/j.jsat.2009.12.008.</citation>
    <PMID>20307795</PMID>
  </reference>
  <reference>
    <citation>Simpson DD. A conceptual framework for drug treatment process and outcomes. J Subst Abuse Treat. 2004 Sep;27(2):99-121.</citation>
    <PMID>15450644</PMID>
  </reference>
  <reference>
    <citation>Andersen R, Chen MS, Aday LA, Cornelius L. Health status and medical care utilization. Health Aff (Millwood). 1987 Spring;6(1):136-56.</citation>
    <PMID>3583214</PMID>
  </reference>
  <reference>
    <citation>Binder T, Vavrinková B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett. 2008 Feb;29(1):80-6.</citation>
    <PMID>18283247</PMID>
  </reference>
  <reference>
    <citation>Winhusen T, Wilder C, Wexelblatt SL, Theobald J, Hall ES, Lewis D, Van Hook J, Marcotte M. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. Contemp Clin Trials. 2014 Sep;39(1):158-65. doi: 10.1016/j.cct.2014.08.009. Epub 2014 Aug 23.</citation>
    <PMID>25183042</PMID>
  </reference>
  <reference>
    <citation>Deverka PA, Lavallee DC, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, Tunis SR. Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res. 2012 Mar;1(2):181-194.</citation>
    <PMID>22707880</PMID>
  </reference>
  <reference>
    <citation>Krans EE, Davis MM. Preventing Low Birthweight: 25 years, prenatal risk, and the failure to reinvent prenatal care. Am J Obstet Gynecol. 2012 May;206(5):398-403. doi: 10.1016/j.ajog.2011.06.082. Epub 2011 Jun 29.</citation>
    <PMID>21889122</PMID>
  </reference>
  <reference>
    <citation>Krans EE, Davis MM, Palladino CL. Disparate patterns of prenatal care utilization stratified by medical and psychosocial risk. Matern Child Health J. 2013 May;17(4):639-45. doi: 10.1007/s10995-012-1040-9.</citation>
    <PMID>22581379</PMID>
  </reference>
  <reference>
    <citation>Krans EE, Davis MM, Schwarz EB. Psychosocial risk, prenatal counseling and maternal behavior: findings from PRAMS, 2004-2008. Am J Obstet Gynecol. 2013 Feb;208(2):141.e1-7. doi: 10.1016/j.ajog.2012.11.017. Epub 2012 Nov 15.</citation>
    <PMID>23159699</PMID>
  </reference>
  <reference>
    <citation>Krans EE, Moloci NM, Housey MT, Davis MM. Impact of psychosocial risk factors on prenatal care delivery: a national provider survey. Matern Child Health J. 2014 Dec;18(10):2362-70. doi: 10.1007/s10995-014-1476-1.</citation>
    <PMID>24740719</PMID>
  </reference>
  <reference>
    <citation>McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199-213.</citation>
    <PMID>1334156</PMID>
  </reference>
  <reference>
    <citation>Etter JF. A comparison of the content-, construct- and predictive validity of the cigarette dependence scale and the Fagerström test for nicotine dependence. Drug Alcohol Depend. 2005 Mar 7;77(3):259-68.</citation>
    <PMID>15734226</PMID>
  </reference>
  <reference>
    <citation>Madden JD, Chappel JN, Zuspan F, Gumpel J, Mejia A, Davis R. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol. 1977 Jan 15;127(2):199-201.</citation>
    <PMID>831502</PMID>
  </reference>
  <reference>
    <citation>Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010 Sep;29(5):551-6. doi: 10.1111/j.1465-3362.2010.00176.x.</citation>
    <PMID>20887580</PMID>
  </reference>
  <reference>
    <citation>Bandstra ES, Morrow CE, Mansoor E, Accornero VH. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis. 2010 Apr;29(2):245-58. doi: 10.1080/10550881003684871. Review.</citation>
    <PMID>20407980</PMID>
  </reference>
  <reference>
    <citation>Creanga AA, Sabel JC, Ko JY, Wasserman CR, Shapiro-Mendoza CK, Taylor P, Barfield W, Cawthon L, Paulozzi LJ. Maternal drug use and its effect on neonates: a population-based study in Washington State. Obstet Gynecol. 2012 May;119(5):924-33. doi: 10.1097/AOG.0b013e31824ea276.</citation>
    <PMID>22525903</PMID>
  </reference>
  <reference>
    <citation>Jones HE, Heil SH, O'Grady KE, Martin PR, Kaltenbach K, Coyle MG, Stine SM, Selby P, Arria AM, Fischer G. Smoking in pregnant women screened for an opioid agonist medication study compared to related pregnant and non-pregnant patient samples. Am J Drug Alcohol Abuse. 2009;35(5):375-80. doi: 10.1080/00952990903125235.</citation>
    <PMID>20180667</PMID>
  </reference>
  <reference>
    <citation>Keegan J, Parva M, Finnegan M, Gerson A, Belden M. Addiction in pregnancy. J Addict Dis. 2010 Apr;29(2):175-91. doi: 10.1080/10550881003684723.</citation>
    <PMID>20407975</PMID>
  </reference>
  <reference>
    <citation>Chisolm MS, Tuten M, Brigham EC, Strain EC, Jones HE. Relationship between cigarette use and mood/anxiety disorders among pregnant methadone-maintained patients. Am J Addict. 2009 Sep-Oct;18(5):422-9. doi: 10.3109/10550490903077721.</citation>
    <PMID>19874163</PMID>
  </reference>
  <reference>
    <citation>Feske U, Tarter RE, Kirisci L, Pilkonis PA. Borderline personality and substance use in women. Am J Addict. 2006 Mar-Apr;15(2):131-7.</citation>
    <PMID>16595350</PMID>
  </reference>
  <reference>
    <citation>Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord. 2007 Apr;99(1-3):213-20. Epub 2006 Oct 19.</citation>
    <PMID>17055063</PMID>
  </reference>
  <reference>
    <citation>Tuten M, Heil SH, O'Grady KE, Fitzsimons H, Chisolm MS, Jones HE. The impact of mood disorders on the delivery and neonatal outcomes of methadone-maintained pregnant patients. Am J Drug Alcohol Abuse. 2009;35(5):358-63. doi: 10.1080/00952990903108231. Erratum in: Am J Drug Alcohol Abuse. 2010 Sep;36(5):304.</citation>
    <PMID>20180664</PMID>
  </reference>
  <reference>
    <citation>Benningfield MM, Arria AM, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Fischer G, Jones HE, Martin PR. Co-occurring psychiatric symptoms are associated with increased psychological, social, and medical impairment in opioid dependent pregnant women. Am J Addict. 2010 Sep-Oct;19(5):416-21. doi: 10.1111/j.1521-0391.2010.00064.x.</citation>
    <PMID>20716304</PMID>
  </reference>
  <reference>
    <citation>Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst Use Misuse. 1999 Jun;34(8):1137-65.</citation>
    <PMID>10359226</PMID>
  </reference>
  <reference>
    <citation>Ashley OS, Marsden ME, Brady TM. Effectiveness of substance abuse treatment programming for women: a review. Am J Drug Alcohol Abuse. 2003;29(1):19-53. Review.</citation>
    <PMID>12731680</PMID>
  </reference>
  <reference>
    <citation>Rowan-Szal GA, Chatham LR, Joe GW, Simpson DD. Services provided during methadone treatment. A gender comparison. J Subst Abuse Treat. 2000 Jul;19(1):7-14.</citation>
    <PMID>10867295</PMID>
  </reference>
  <reference>
    <citation>Latt NC, Spencer JD, Beeby PJ, McCaughan GW, Saunders JB, Collins E, Cossart YE. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol. 2000 Feb;15(2):175-81.</citation>
    <PMID>10735542</PMID>
  </reference>
  <reference>
    <citation>Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998 Nov;92(5):854-8.</citation>
    <PMID>9794682</PMID>
  </reference>
  <reference>
    <citation>Stewart RD, Nelson DB, Adhikari EH, McIntire DD, Roberts SW, Dashe JS, Sheffield JS. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013 Sep;209(3):267.e1-5. doi: 10.1016/j.ajog.2013.05.026. Epub 2013 May 29.</citation>
    <PMID>23727040</PMID>
  </reference>
  <reference>
    <citation>Jones HE, Finnegan LP, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012 Apr 16;72(6):747-57. doi: 10.2165/11632820-000000000-00000. Review.</citation>
    <PMID>22512363</PMID>
  </reference>
  <reference>
    <citation>Jones HE, Deppen K, Hudak ML, Leffert L, McClelland C, Sahin L, Starer J, Terplan M, Thorp JM Jr, Walsh J, Creanga AA. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014 Apr;210(4):302-310. doi: 10.1016/j.ajog.2013.10.010. Epub 2013 Oct 10.</citation>
    <PMID>24120973</PMID>
  </reference>
  <reference>
    <citation>Krans EE, Cochran G, Bogen DL. Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. Clin Obstet Gynecol. 2015 Jun;58(2):370-9. doi: 10.1097/GRF.0000000000000098.</citation>
    <PMID>25775440</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Elizabeth Krans, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Department of Obstetrics, Gynecology &amp; Reproductive Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

